Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2002 Nov;61(Suppl 3):iii8–iii18. doi: 10.1136/ard.61.suppl_3.iii8

Ankylosing spondylitis: an overview

J Sieper, J Braun, M Rudwaleit, A Boonen, A Zink
PMCID: PMC1766729  PMID: 12381506

Abstract

Ankylosing spondylitis (AS) is a complex, potentially debilitating disease that is insidious in onset, progressing to radiological sacroiliitis over several years. Patients with symptomatic AS lose productivity owing to work disability and unemployment, have a substantial use of healthcare resources, and reduced quality of life. The pathogenesis of AS is poorly understood. However, immune mediated mechanisms involving human leucocyte antigen (HLA)-B27, inflammatory cellular infiltrates, cytokines (for example, tumour necrosis factor α and interleukin 10), and genetic and environmental factors are thought to have key roles. The detection of sacroiliitis by radiography, magnetic resonance imaging, or computed tomography in the presence of clinical manifestations is diagnostic for AS, although the presence of inflammatory back pain plus at least two other typical features of spondyloarthropathy (for example, enthesitis and uveitis) is highly predictive of early AS. Non-steroidal anti-inflammatory drugs (NSAIDs) effectively relieve inflammatory symptoms and are presently first line drug treatment. However, NSAID treatment has only a symptomatic effect and probably does not alter the disease course. For symptoms refractory to NSAIDs, second line treatments, including corticosteroids and various disease modifying antirheumatic drugs, are employed but are of limited benefit. Emerging biological therapies target the inflammatory processes underlying AS, and thus, may favourably alter the disease process, in addition to providing symptom relief.

Full Text

The Full Text of this article is available as a PDF (269.1 KB).

Figure 1 .

Figure 1

Open in a new tab

Evolution from undifferentiated spondyloarthropathy (uSpA) to ankylosing spondylitis (AS) in patients with definitive radiological sacroiliitis.69 This previously unpublished figure is based on data published by Dr W Mau and is printed with the author's permission.

Figure 2 .

Figure 2

Open in a new tab

A biopsy specimen from a patient with acute sacroiliitis shows cellular infiltrate containing activated fibroblasts and lymphocytes that seem to invade a degenerate cartilaginous area.94 Reproduced with permission of the author and the copyright holders from reference 94. Copyright © 2000 by the Annals of the Rheumatic Diseases.

Figure 3 .

Figure 3

Open in a new tab

Pelvic radiograph of a patient with AS showing sacroiliitis grade II on the right side and grade II–III on the left. This previously unpublished figure is provided courtesy of Dr M Rudwaleit.

Figure 4 .

Figure 4

Open in a new tab

Pelvic radiograph of a patient with AS showing bilateral sacroiliitis grade III. This previously unpublished figure is provided courtesy of Dr M Rudwaleit.

Figure 5 .

Figure 5

Open in a new tab

Pelvic radiograph (A) showing suspicious changes: a small circumscribed zone of sclerosis of the left sacroiliac joint (sacroiliitis grade I–II) and slightly blurred joint margins of the right sacroiliac joint (grade I). The corresponding MRI (B) of the sacroiliac joints shows contrast enhancement of periarticular bone (oedema) and of the joint space of both sacroiliac joints reflecting acute inflammation (subtraction technique after intravenous application of gadolinium). These previously unpublished figures are provided courtesy of Dr M Rudwaleit.

Figure 6 .

Figure 6

Open in a new tab

Diagnostic algorithm for axial SpA (early AS) starting with the assessment of inflammatory back pain. The combination of several typical SpA manifestations results in a high disease probability. This figure will be published in Ankylosing spondylitis: clinical features. In: Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman M, eds. Rheumatology. 3rd ed. London: Mosby: a division of Harcourt Health Sciences Ltd, ©2002. Reproduced with permission from Dr M A Khan and Mosby.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahvonen P., Sievers K., Aho K. Arthritis associated with Yersinia enterocolitica infection. Acta Rheumatol Scand. 1969;15(3):232–253. doi: 10.3109/rhe1.1969.15.issue-1-4.32. [DOI] [PubMed] [Google Scholar]
  2. Altan L., Bingöl U., Karakoç Y., Aydiner S., Yurtkuran M., Yurtkuran M. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol. 2001;30(5):255–259. doi: 10.1080/030097401753180318. [DOI] [PubMed] [Google Scholar]
  3. Amor B., Santos R. S., Nahal R., Listrat V., Dougados M. Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol. 1994 Oct;21(10):1883–1887. [PubMed] [Google Scholar]
  4. Arnett F. C. Ankylosing spondylitis 1992: from Connor to transgenes. J Ir Coll Physicians Surg. 1993 Jul;22(3):207–211. [PubMed] [Google Scholar]
  5. Arnett F. C. Seronegative spondylarthropathies. Bull Rheum Dis. 1987;37(1):1–12. [PubMed] [Google Scholar]
  6. Ball E. J., Khan M. A. HLA-B27 polymorphism. Joint Bone Spine. 2001 Oct;68(5):378–382. doi: 10.1016/s1297-319x(01)00294-9. [DOI] [PubMed] [Google Scholar]
  7. Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis. 1971 May;30(3):213–223. doi: 10.1136/ard.30.3.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Barlow J. H., Wright C. C., Williams B., Keat A. Work disability among people with ankylosing spondylitis. Arthritis Rheum. 2001 Oct;45(5):424–429. doi: 10.1002/1529-0131(200110)45:5<424::aid-art361>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  9. Benjamin M., McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J Anat. 2001 Nov;199(Pt 5):503–526. doi: 10.1046/j.1469-7580.2001.19950503.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Benjamin S. B., Ishak K. G., Zimmerman H. J., Grushka A. Phenylbutazone liver injury: a clinical-pathologic survey of 23 cases and review of the literature. Hepatology. 1981 May-Jun;1(3):255–263. doi: 10.1002/hep.1840010311. [DOI] [PubMed] [Google Scholar]
  11. Biasi D., Carletto A., Caramaschi P., Pacor M. L., Maleknia T., Bambara L. M. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol. 2000;19(2):114–117. doi: 10.1007/s100670050027. [DOI] [PubMed] [Google Scholar]
  12. Bird H. A., Le Gallez P., Astbury C., Looi D., Wright V. A parallel group comparison of tenoxicam and piroxicam in patients with ankylosing spondylitis. Pharmatherapeutica. 1986;4(7):457–462. [PubMed] [Google Scholar]
  13. Blum U., Buitrago-Tellez C., Mundinger A., Krause T., Laubenberger J., Vaith P., Peter H. H., Langer M. Magnetic resonance imaging (MRI) for detection of active sacroiliitis--a prospective study comparing conventional radiography, scintigraphy, and contrast enhanced MRI. J Rheumatol. 1996 Dec;23(12):2107–2115. [PubMed] [Google Scholar]
  14. Bollow M., Fischer T., Reisshauer H., Backhaus M., Sieper J., Hamm B., Braun J. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis. 2000 Feb;59(2):135–140. doi: 10.1136/ard.59.2.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Boonen A., Chorus A., Miedema H., van der Heijde D., Landewé R., Schouten H., van der Tempel H., van der Linden S. Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Ann Rheum Dis. 2001 Nov;60(11):1033–1039. doi: 10.1136/ard.60.11.1033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Boonen A., Chorus A., Miedema H., van der Heijde D., van der Tempel H., van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis. 2001 Apr;60(4):353–358. doi: 10.1136/ard.60.4.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Boonen A., de Vet H., van der Heijde D., van der Linden S. Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review. J Rheumatol. 2001 May;28(5):1056–1062. [PubMed] [Google Scholar]
  18. Boonen A., van der Heijde D., Landewé R., Spoorenberg A., Schouten H., Rutten-van Mölken M., Guillemin F., Dougados M., Mielants H., de Vlam K. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis. 2002 May;61(5):429–437. doi: 10.1136/ard.61.5.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Boyer G. S., Templin D. W., Cornoni-Huntley J. C., Everett D. F., Lawrence R. C., Heyse S. F., Miller M. M., Goring W. P. Prevalence of spondyloarthropathies in Alaskan Eskimos. J Rheumatol. 1994 Dec;21(12):2292–2297. [PubMed] [Google Scholar]
  20. Braun J., Bollow M., Eggens U., König H., Distler A., Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum. 1994 Jul;37(7):1039–1045. doi: 10.1002/art.1780370709. [DOI] [PubMed] [Google Scholar]
  21. Braun J., Bollow M., Remlinger G., Eggens U., Rudwaleit M., Distler A., Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum. 1998 Jan;41(1):58–67. doi: 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G. [DOI] [PubMed] [Google Scholar]
  22. Braun J., Bollow M., Seyrekbasan F., Häberle H. J., Eggens U., Mertz A., Distler A., Sieper J. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol. 1996 Apr;23(4):659–664. [PubMed] [Google Scholar]
  23. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002 Apr 6;359(9313):1187–1193. doi: 10.1016/s0140-6736(02)08215-6. [DOI] [PubMed] [Google Scholar]
  24. Braun J., Sieper J. Inzeptionskohorte für Spondylarthropathien. Z Rheumatol. 2000 Apr;59(2):117–121. doi: 10.1007/s003930050215. [DOI] [PubMed] [Google Scholar]
  25. Braun J., Yin Z., Spiller I., Siegert S., Rudwaleit M., Liu L., Radbruch A., Sieper J. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum. 1999 Oct;42(10):2039–2044. doi: 10.1002/1529-0131(199910)42:10<2039::AID-ANR3>3.0.CO;2-6. [DOI] [PubMed] [Google Scholar]
  26. Braunstein E. M., Martel W., Moidel R. Ankylosing spondylitis in men and women: a clinical and radiographic comparison. Radiology. 1982 Jul;144(1):91–94. doi: 10.1148/radiology.144.1.7089271. [DOI] [PubMed] [Google Scholar]
  27. Breban M. Genetic studies of spondylarthropathies. French Spondylarthropathy Genetic Study Group. Ann Med Interne (Paris) 1998 Apr;149(3):142–144. [PubMed] [Google Scholar]
  28. Brewerton D. A., Caffrey M., Nicholls A., Walters D., Oates J. K., James D. C. Reiter's disease and HL-A 27. Lancet. 1973 Nov 3;302(7836):996–998. doi: 10.1016/s0140-6736(73)91091-x. [DOI] [PubMed] [Google Scholar]
  29. Brophy S., Calin A. Ankylosing spondylitis: interaction between genes, joints, age at onset, and disease expression. J Rheumatol. 2001 Oct;28(10):2283–2288. [PubMed] [Google Scholar]
  30. Brophy S., Pavy S., Lewis P., Taylor G., Bradbury L., Robertson D., Lovell C., Calin A. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. J Rheumatol. 2001 Dec;28(12):2667–2673. [PubMed] [Google Scholar]
  31. Brown M. A., Kennedy L. G., MacGregor A. J., Darke C., Duncan E., Shatford J. L., Taylor A., Calin A., Wordsworth P. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum. 1997 Oct;40(10):1823–1828. doi: 10.1002/art.1780401015. [DOI] [PubMed] [Google Scholar]
  32. Burgos-Vargas R., Naranjo A., Castillo J., Katona G. Ankylosing spondylitis in the Mexican mestizo: patterns of disease according to age at onset. J Rheumatol. 1989 Feb;16(2):186–191. [PubMed] [Google Scholar]
  33. Burgos-Vargas R., Pacheco-Tena C., Vázquez-Mellado J. Juvenile-onset spondyloarthropathies. Rheum Dis Clin North Am. 1997 Aug;23(3):569–598. doi: 10.1016/s0889-857x(05)70348-3. [DOI] [PubMed] [Google Scholar]
  34. Calin A. Clinical use of tolmetin sodium in patients with ankylosing spondylitis: a review. J Clin Pharmacol. 1983 Jul;23(7):301–308. doi: 10.1002/j.1552-4604.1983.tb02740.x. [DOI] [PubMed] [Google Scholar]
  35. Calin A., Porta J., Fries J. F., Schurman D. J. Clinical history as a screening test for ankylosing spondylitis. JAMA. 1977 Jun 13;237(24):2613–2614. [PubMed] [Google Scholar]
  36. Carette S., Graham D., Little H., Rubenstein J., Rosen P. The natural disease course of ankylosing spondylitis. Arthritis Rheum. 1983 Feb;26(2):186–190. doi: 10.1002/art.1780260210. [DOI] [PubMed] [Google Scholar]
  37. Chou C. T. Factors affecting the pathogenesis of ankylosing spondylitis. Chin Med J (Engl) 2001 Feb;114(2):211–212. [PubMed] [Google Scholar]
  38. Cooper N. J. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000 Jan;39(1):28–33. doi: 10.1093/rheumatology/39.1.28. [DOI] [PubMed] [Google Scholar]
  39. Dougados M., Gueguen A., Nakache J. P., Velicitat P., Veys E. M., Zeidler H., Calin A. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999 Mar;38(3):235–244. doi: 10.1093/rheumatology/38.3.235. [DOI] [PubMed] [Google Scholar]
  40. Dougados M., Gueguen A., Nakache J. P., Velicitat P., Zeidler H., Veys E., Calin A. Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis. J Rheumatol. 1999 Apr;26(4):971–974. [PubMed] [Google Scholar]
  41. Dougados M., Revel M., Khan M. A. Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillieres Clin Rheumatol. 1998 Nov;12(4):717–736. doi: 10.1016/s0950-3579(98)80046-0. [DOI] [PubMed] [Google Scholar]
  42. Dougados M., vam der Linden S., Leirisalo-Repo M., Huitfeldt B., Juhlin R., Veys E., Zeidler H., Kvien T. K., Olivieri I., Dijkmans B. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995 May;38(5):618–627. doi: 10.1002/art.1780380507. [DOI] [PubMed] [Google Scholar]
  43. Dougados M., van der Linden S., Juhlin R., Huitfeldt B., Amor B., Calin A., Cats A., Dijkmans B., Olivieri I., Pasero G. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991 Oct;34(10):1218–1227. doi: 10.1002/art.1780341003. [DOI] [PubMed] [Google Scholar]
  44. Ebringer R. W., Cawdell D. R., Cowling P., Ebringer A. Sequential studies in ankylosing spondylitis. Association of Klebsiella pneumoniae with active disease. Ann Rheum Dis. 1978 Apr;37(2):146–151. doi: 10.1136/ard.37.2.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Feldtkeller E. Erkrankungsalter und Diagnoseverzögerung bei Spondylarthropathien. Z Rheumatol. 1999 Feb;58(1):21–30. doi: 10.1007/s003930050149. [DOI] [PubMed] [Google Scholar]
  46. Fellmann J. Wege und Irrwege in der Geschichte der Spondylitis ankylosans. Schweiz Rundsch Med Prax. 1991 May 21;80(21):576–579. [PubMed] [Google Scholar]
  47. Feltkamp T. E., Mardjuadi A., Huang F., Chou C. T. Spondyloarthropathies in eastern Asia. Curr Opin Rheumatol. 2001 Jul;13(4):285–290. doi: 10.1097/00002281-200107000-00007. [DOI] [PubMed] [Google Scholar]
  48. Franssen M. J., Gribnau F. W., van de Putte L. B. A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis. Clin Rheumatol. 1986 Jun;5(2):210–220. doi: 10.1007/BF02032359. [DOI] [PubMed] [Google Scholar]
  49. François R. J., Braun J., Khan M. A. Entheses and enthesitis: a histopathologic review and relevance to spondyloarthritides. Curr Opin Rheumatol. 2001 Jul;13(4):255–264. doi: 10.1097/00002281-200107000-00003. [DOI] [PubMed] [Google Scholar]
  50. François R. J., Eulderink F., Bywaters E. G. Commented glossary for rheumatic spinal diseases, based on pathology. Ann Rheum Dis. 1995 Aug;54(8):615–625. doi: 10.1136/ard.54.8.615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. François R. J., Gardner D. L., Degrave E. J., Bywaters E. G. Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum. 2000 Sep;43(9):2011–2024. doi: 10.1002/1529-0131(200009)43:9<2011::AID-ANR12>3.0.CO;2-Y. [DOI] [PubMed] [Google Scholar]
  52. Gaston J. S., Life P. F., Granfors K., Merilahti-Palo R., Bailey L., Consalvey S., Toivanen A., Bacon P. A. Synovial T lymphocyte recognition of organisms that trigger reactive arthritis. Clin Exp Immunol. 1989 Jun;76(3):348–353. [PMC free article] [PubMed] [Google Scholar]
  53. Gonzalez-Roces S., Alvarez M. V., Gonzalez S., Dieye A., Makni H., Woodfield D. G., Housan L., Konenkov V., Abbadi M. C., Grunnet N. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens. 1997 Feb;49(2):116–123. doi: 10.1111/j.1399-0039.1997.tb02724.x. [DOI] [PubMed] [Google Scholar]
  54. Good A., Mena H. Treatment of ankylosing spondylitis with flurbiprofen and indomethacin. Curr Med Res Opin. 1977;5(1):117–121. doi: 10.1185/03007997709108987. [DOI] [PubMed] [Google Scholar]
  55. Gran J. T., Husby G., Hordvik M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromsø, northern Norway. Ann Rheum Dis. 1985 Jun;44(6):359–367. doi: 10.1136/ard.44.6.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Günaydin I., Pereira P. L., Daikeler T., Mohren M., Trübenbach J., Schick F., Kanz L., Kötter I. Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. J Rheumatol. 2000 Feb;27(2):424–428. [PubMed] [Google Scholar]
  57. HART F. D., ROBINSON K. C. Ankylosing spondylitis in women. Ann Rheum Dis. 1959 Mar;18(1):15–23. doi: 10.1136/ard.18.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Hammer R. E., Maika S. D., Richardson J. A., Tang J. P., Taurog J. D. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell. 1990 Nov 30;63(5):1099–1112. doi: 10.1016/0092-8674(90)90512-d. [DOI] [PubMed] [Google Scholar]
  59. Hart F. D., Boardman P. L. Indomethacin and phenylbutazone: a comparison. Br Med J. 1965 Nov 27;2(5473):1281–1284. doi: 10.1136/bmj.2.5473.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Hoyle E., Laval S. H., Calin A., Wordsworth B. P., Brown M. A. The X-chromosome and susceptibility to ankylosing spondylitis. Arthritis Rheum. 2000 Jun;43(6):1353–1355. doi: 10.1002/1529-0131(200006)43:6<1353::AID-ANR19>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  61. Hukuda S., Minami M., Saito T., Mitsui H., Matsui N., Komatsubara Y., Makino H., Shibata T., Shingu M., Sakou T. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol. 2001 Mar;28(3):554–559. [PubMed] [Google Scholar]
  62. Inman W. H. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. Br Med J. 1977 Jun 11;1(6075):1500–1505. doi: 10.1136/bmj.1.6075.1500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Jardetzky T. S., Lane W. S., Robinson R. A., Madden D. R., Wiley D. C. Identification of self peptides bound to purified HLA-B27. Nature. 1991 Sep 26;353(6342):326–329. doi: 10.1038/353326a0. [DOI] [PubMed] [Google Scholar]
  64. Jiménez-Balderas F. J., Mintz G. Ankylosing spondylitis: clinical course in women and men. J Rheumatol. 1993 Dec;20(12):2069–2072. [PubMed] [Google Scholar]
  65. Kaipiainen-Seppanen O., Aho K., Heliovaara M. Incidence and prevalence of ankylosing spondylitis in Finland. J Rheumatol. 1997 Mar;24(3):496–499. [PubMed] [Google Scholar]
  66. Khan M. A. A double blind comparison of diclofenac and indomethacin in the treatment of ankylosing spondylitis. J Rheumatol. 1987 Feb;14(1):118–123. [PubMed] [Google Scholar]
  67. Khan M. A., Khan M. K. Diagnostic value of HLA-B27 testing ankylosing spondylitis and Reiter's syndrome. Ann Intern Med. 1982 Jan;96(1):70–76. doi: 10.7326/0003-4819-96-1-70. [DOI] [PubMed] [Google Scholar]
  68. Laloux L., Voisin M. C., Allain J., Martin N., Kerboull L., Chevalier X., Claudepierre P. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis. 2001 Apr;60(4):316–321. doi: 10.1136/ard.60.4.316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Langman M. J., Jensen D. M., Watson D. J., Harper S. E., Zhao P. L., Quan H., Bolognese J. A., Simon T. J. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999 Nov 24;282(20):1929–1933. doi: 10.1001/jama.282.20.1929. [DOI] [PubMed] [Google Scholar]
  70. Laval S. H., Timms A., Edwards S., Bradbury L., Brophy S., Milicic A., Rubin L., Siminovitch K. A., Weeks D. E., Calin A. Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. Am J Hum Genet. 2001 Feb 27;68(4):918–926. doi: 10.1086/319509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Lockie L. M. Tolerability and efficacy of long-term daily administration of indomethacin for moderate to severe chronic arthritic disorders. Clin Ther. 1986;8(4):398–405. [PubMed] [Google Scholar]
  72. Lomen P. L., Turner L. F., Lamborn K. R., Brinn E. L., Sattler L. P. Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with phenylbutazone. Am J Med. 1986 Mar 24;80(3A):120–126. doi: 10.1016/0002-9343(86)90128-2. [DOI] [PubMed] [Google Scholar]
  73. Madden D. R., Gorga J. C., Strominger J. L., Wiley D. C. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature. 1991 Sep 26;353(6342):321–325. doi: 10.1038/353321a0. [DOI] [PubMed] [Google Scholar]
  74. Maksymowych W. P. Ankylosing spondylitis--at the interface of bone and cartilage. J Rheumatol. 2000 Oct;27(10):2295–2301. [PubMed] [Google Scholar]
  75. Martínez-Borra J., González S., López-Larrea C. Genetic factors predisposing to spondylarthropathies. Arthritis Rheum. 2000 Mar;43(3):485–492. doi: 10.1002/1529-0131(200003)43:3<485::AID-ANR2>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  76. Mau W., Zeidler H., Mau R., Majewski A., Freyschmidt J., Stangel W., Deicher H. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol. 1988 Jul;15(7):1109–1114. [PubMed] [Google Scholar]
  77. Maugars Y., Mathis C., Berthelot J. M., Charlier C., Prost A. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol. 1996 Aug;35(8):767–770. doi: 10.1093/rheumatology/35.8.767. [DOI] [PubMed] [Google Scholar]
  78. McBryde A. M., Jr, McCollum D. E. Ankylosing spondylitis in women. The disease and its prognosis. N C Med J. 1973 Jan;34(1):34–37. [PubMed] [Google Scholar]
  79. Mena H. R., Willkens R. F. Treatment of ankylosing spondylitis with flurbiprofen or phenylbutazone. Eur J Clin Pharmacol. 1977 Apr 20;11(4):263–266. doi: 10.1007/BF00607674. [DOI] [PubMed] [Google Scholar]
  80. Mielants H., Veys E. M., Cuvelier C., De Vos M. Course of gut inflammation in spondylarthropathies and therapeutic consequences. Baillieres Clin Rheumatol. 1996 Feb;10(1):147–164. doi: 10.1016/s0950-3579(96)80010-0. [DOI] [PubMed] [Google Scholar]
  81. Mielants H., Veys E. M., Joos R., Cuvelier C., De Vos M. Repeat ileocolonoscopy in reactive arthritis. J Rheumatol. 1987 Jun;14(3):456–458. [PubMed] [Google Scholar]
  82. Mielants H., Veys E. M., Joos R., Noens L., Cuvelier C., De Vos M. HLA antigens in seronegative spondylarthropathies. Reactive arthritis and arthritis in ankylosing spondylitis: relation to gut inflammation. J Rheumatol. 1987 Jun;14(3):466–471. [PubMed] [Google Scholar]
  83. Moll J. M., Haslock I., Macrae I. F., Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome. Medicine (Baltimore) 1974 Sep;53(5):343–364. doi: 10.1097/00005792-197409000-00002. [DOI] [PubMed] [Google Scholar]
  84. Moreland L. W., Russell A. S., Paulus H. E. Management of rheumatoid arthritis: the historical context. J Rheumatol. 2001 Jun;28(6):1431–1452. [PubMed] [Google Scholar]
  85. Mori K., Ushiyama T., Inoue K., Hukuda S. Polymorphic CAG repeats of the androgen receptor gene in Japanese male patients with ankylosing spondylitis. Rheumatology (Oxford) 2000 May;39(5):530–532. doi: 10.1093/rheumatology/39.5.530. [DOI] [PubMed] [Google Scholar]
  86. Mäki-Ikola O., Lehtinen K., Granfors K., Vainionpä R., Toivanen P. Bacterial antibodies in ankylosing spondylitis. Clin Exp Immunol. 1991 Jun;84(3):472–475. [PMC free article] [PubMed] [Google Scholar]
  87. Oostveen J., Prevo R., den Boer J., van de Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study. J Rheumatol. 1999 Sep;26(9):1953–1958. [PubMed] [Google Scholar]
  88. Pacheco-Tena C., Alvarado De La Barrera C., López-Vidal Y., Vázquez-Mellado J., Richaud-Patin Y., Amieva R. I., Llorente L., Martínez A., Zúiga J., Cifuentes-Alvarado M. Bacterial DNA in synovial fluid cells of patients with juvenile onset spondyloarthropathies. Rheumatology (Oxford) 2001 Aug;40(8):920–927. doi: 10.1093/rheumatology/40.8.920. [DOI] [PubMed] [Google Scholar]
  89. Palferman T. G., Webley M. A comparative study of nabumetone and indomethacin in ankylosing spondylitis. Eur J Rheumatol Inflamm. 1991;11(2):23–29. [PubMed] [Google Scholar]
  90. Peters N. D., Ejstrup L. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol. 1992;21(3):134–138. doi: 10.3109/03009749209095085. [DOI] [PubMed] [Google Scholar]
  91. Resnick D., Dwosh I. L., Goergen T. G., Shapiro R. F., Utsinger P. D., Wiesner K. B., Bryan B. L. Clinical and radiographic abnormalities in ankylosing spondylitis: a comparison of men and women. Radiology. 1976 May;119(2):293–297. doi: 10.1148/119.2.293. [DOI] [PubMed] [Google Scholar]
  92. Reveille J. D., Ball E. J., Khan M. A. HLA-B27 and genetic predisposing factors in spondyloarthropathies. Curr Opin Rheumatol. 2001 Jul;13(4):265–272. doi: 10.1097/00002281-200107000-00004. [DOI] [PubMed] [Google Scholar]
  93. Rudwaleit M., Höhler T. Cytokine gene polymorphisms relevant for the spondyloarthropathies. Curr Opin Rheumatol. 2001 Jul;13(4):250–254. doi: 10.1097/00002281-200107000-00002. [DOI] [PubMed] [Google Scholar]
  94. Rudwaleit M., Siegert S., Yin Z., Eick J., Thiel A., Radbruch A., Sieper J., Braun J. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis. 2001 Jan;60(1):36–42. doi: 10.1136/ard.60.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Ruof J., Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol. 1999 Apr;26(4):966–970. [PubMed] [Google Scholar]
  96. Sampaio-Barros P. D., Costallat L. T., Bertolo M. B., Neto J. F., Samara A. M. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol. 2000;29(3):160–162. doi: 10.1080/030097400750002021. [DOI] [PubMed] [Google Scholar]
  97. Schlosstein L., Terasaki P. I., Bluestone R., Pearson C. M. High association of an HL-A antigen, W27, with ankylosing spondylitis. N Engl J Med. 1973 Apr 5;288(14):704–706. doi: 10.1056/NEJM197304052881403. [DOI] [PubMed] [Google Scholar]
  98. Schmitt E., Rückbeil C., Wick R. R. Long-term clinical investigation of patients with ankylosing spondylitis treated with 224Ra. Health Phys. 1983;44 (Suppl 1):197–202. doi: 10.1097/00004032-198306001-00016. [DOI] [PubMed] [Google Scholar]
  99. Schwarzer A. C., Cohen M., Arnold M. H., Kelly D., McNaught P., Brooks P. M. Tenoxicam compared with diclofenac in patients with ankylosing spondylitis. Curr Med Res Opin. 1990;11(10):648–653. doi: 10.1185/03007999009112691. [DOI] [PubMed] [Google Scholar]
  100. Sieper J., Braun J., Kingsley G. H. Report on the Fourth International Workshop on Reactive Arthritis. Arthritis Rheum. 2000 Apr;43(4):720–734. doi: 10.1002/1529-0131(200004)43:4<720::AID-ANR2>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  101. Sieper J., Braun J. Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both? Arthritis Rheum. 1995 Nov;38(11):1547–1554. doi: 10.1002/art.1780381105. [DOI] [PubMed] [Google Scholar]
  102. Simon A. K., Seipelt E., Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8562–8566. doi: 10.1073/pnas.91.18.8562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Simon L. S., Weaver A. L., Graham D. Y., Kivitz A. J., Lipsky P. E., Hubbard R. C., Isakson P. C., Verburg K. M., Yu S. S., Zhao W. W. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999 Nov 24;282(20):1921–1928. doi: 10.1001/jama.282.20.1921. [DOI] [PubMed] [Google Scholar]
  104. Smith P. G., Doll R. Mortality among patients with ankylosing spondylitis after a single treatment course with x rays. Br Med J (Clin Res Ed) 1982 Feb 13;284(6314):449–460. doi: 10.1136/bmj.284.6314.449. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Spoorenberg A., van der Heijde D., de Klerk E., Dougados M., de Vlam K., Mielants H., van der Tempel H., van der Linden S. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol. 1999 Apr;26(4):980–984. [PubMed] [Google Scholar]
  106. Stafford L., Youssef P. P. Spondyloarthropathies: an overview. Intern Med J. 2002 Jan-Feb;32(1-2):40–46. [PubMed] [Google Scholar]
  107. Standel W., Josenhants G. Clinical evaluation of tenoxicam in osteoarthrosis, rheumatoid arthritis and ankylosing spondylitis. Eur J Rheumatol Inflamm. 1985;8(1):28–38. [PubMed] [Google Scholar]
  108. Taggart A., Gardiner P., McEvoy F., Hopkins R., Bird H. Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study. Arthritis Rheum. 1996 Aug;39(8):1400–1405. doi: 10.1002/art.1780390819. [DOI] [PubMed] [Google Scholar]
  109. Taylor H. G., Wardle T., Beswick E. J., Dawes P. T. The relationship of clinical and laboratory measurements to radiological change in ankylosing spondylitis. Br J Rheumatol. 1991 Oct;30(5):330–335. doi: 10.1093/rheumatology/30.5.330. [DOI] [PubMed] [Google Scholar]
  110. Thiel A., Wu P., Lauster R., Braun J., Radbruch A., Sieper J. Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis Rheum. 2000 Dec;43(12):2834–2842. doi: 10.1002/1529-0131(200012)43:12<2834::AID-ANR25>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  111. Thomson G. T., Thomson B. R., Thomson K. S., Ducharme J. S. Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J Rheumatol. 2000 Mar;27(3):714–718. [PubMed] [Google Scholar]
  112. Underwood M. R., Dawes P. Inflammatory back pain in primary care. Br J Rheumatol. 1995 Nov;34(11):1074–1077. doi: 10.1093/rheumatology/34.11.1074. [DOI] [PubMed] [Google Scholar]
  113. Van Gerwen F., Van der Korst J. K., Gribnau F. W. Double-blind trial of naproxen and phenylbutazone in ankylosing spondylitis. Ann Rheum Dis. 1978 Feb;37(1):85–88. doi: 10.1136/ard.37.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Ward M. M. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res. 1999 Aug;12(4):247–255. [PubMed] [Google Scholar]
  115. Ward M. M., Kuzis S. Risk factors for work disability in patients with ankylosing spondylitis. J Rheumatol. 2001 Feb;28(2):315–321. [PubMed] [Google Scholar]
  116. Ward Michael M. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum. 2002 Jan;46(1):223–231. doi: 10.1002/1529-0131(200201)46:1<223::AID-ART498>3.0.CO;2-#. [DOI] [PubMed] [Google Scholar]
  117. Weiss H. A., Darby S. C., Doll R. Cancer mortality following X-ray treatment for ankylosing spondylitis. Int J Cancer. 1994 Nov 1;59(3):327–338. doi: 10.1002/ijc.2910590307. [DOI] [PubMed] [Google Scholar]
  118. Weiss H. A., Darby S. C., Fearn T., Doll R. Leukemia mortality after X-ray treatment for ankylosing spondylitis. Radiat Res. 1995 Apr;142(1):1–11. [PubMed] [Google Scholar]
  119. Wick R. R., Gössner W. Follow-up study of late effects in 224Ra treated ankylosing spondylitis patients. Health Phys. 1983;44 (Suppl 1):187–195. doi: 10.1097/00004032-198306001-00015. [DOI] [PubMed] [Google Scholar]
  120. Zeidler H., Mau W., Khan M. A. Undifferentiated spondyloarthropathies. Rheum Dis Clin North Am. 1992 Feb;18(1):187–202. [PubMed] [Google Scholar]
  121. Zink A., Braun J., Listing J., Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol. 2000 Mar;27(3):613–622. [PubMed] [Google Scholar]
  122. van der Linden S. M., Valkenburg H. A., de Jongh B. M., Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population. Arthritis Rheum. 1984 Mar;27(3):241–249. doi: 10.1002/art.1780270301. [DOI] [PubMed] [Google Scholar]
  123. van der Linden S., Valkenburg H. A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984 Apr;27(4):361–368. doi: 10.1002/art.1780270401. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES